Table 1.
Baseline patient characteristics
| Parameter | Non-EM AML | EM AML | p |
|---|---|---|---|
| n/N (%) | 1358/1583 (85.79) | 225/1583 (14.21) | |
| Age (years), median (IQR) | 53 (42–60) | 53 (42–61) | 0.7652 |
| Sex, n (%) | 0.7730 | ||
| Female | 656 (48.31) | 106 (47.11) | |
| Male | 702 (51.69) | 119 (52.89) | |
| Disease status, n (%) | 0.6587 | ||
| De novo | 1154 (84.98) | 196 (87.11) | |
| sAML | 143 (10.53) | 21 (9.33) | |
| tAML | 45 (3.31) | 7 (3.11) | |
| ELN-Risk 2017, n (%) | 0.0817 | ||
| Favorable | 423 (31.15) | 81 (36.0) | |
| Intermediate | 412 (30.34) | 77 (34.22) | |
| Adverse | 425 (31.30) | 56 (24.89) | |
| Complex karyotype, n (%) | 0.535 | ||
| No | 1106 (81.44) | 201 (89.33) | |
| Yes | 122 (8.93) | 18 (8.0) | |
| Normal karyotype, n (%) | 0.504 | ||
| No | 535 (39.40) | 88 (39.11) | |
| Yes | 727 (53.53) | 129 (57.33) | |
| Laboratory, median (IQR) | |||
| WBC (109/l) | 14.5 (3.3–47.2) | 32.24 (11.1–87.0) | < 0.0001 |
| HB (mmol/l) | 5.9 (5.0–7.1) | 5.9 (5.1–7.0) | 0.5814 |
| PLT (109/l) | 52 (28–96.5) | 53 (28–94) | 0.8999 |
| LDH (U/l) | 429 (260–724) | 605 (462–1008) | < 0.0001 |
| PBB (%) | 33 (8–70) | 55 (19–79.5) | < 0.0001 |
| BMB (%) | 63 (43–79) | 68.5 (47.5–82.5) | 0.019 |
Bold typing indicates statistical significance (p < 0.05)
AML acute myeloid leukemia, sAML secondary AML, tAML therapy-associated AML, BMB bone marrow blasts, EM extramedullary, HB hemoglobin, IQR interquartile range, n/N number, PBB peripheral blood blasts, PLT platelet count, WBC white blood cell count.